The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...

Duchenne muscular dystrophy (DMD) treatment ifetroban led to improvements in measures of heart function in a Phase 2 clinical ...

Duchenne muscular dystrophy (DMD) is the most common type ... to walk for 2 to 5 years longer than they would without it. The drugs also can help your child’s heart and lungs work better.

FSHD is the second most common form of muscular dystrophy after the Duchenne type ... which specialises in acquiring "undervalued" clinical-stage drugs languishing in the pipelines of biopharma ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

Limb-girdle muscular dystrophy type 2D (LGMD2D/R3) is a rare genetic disorder caused by mutations in the SGCA gene, leading to defective folding and the loss of functional α-sarcoglycan, with ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

The GoFundMe page was set up to raise money to cover the cost of life-saving treatment for the 14-year-old boys, who suffer ...

In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...